Cefoselis sulfate

BeschreibungCefoselis is a new fourth-generation cephalosporin and was launched in Japan as a parenteral antibiotic for a variety of infections including Staphylococcus aureus (particularly the methicillin-resistant MRSA) and Pseudornonas aeruginosa. It can be prepared in 3 related ways, all using 2- pyrazolomethyl-3-cephem-4-carboxylic as the key intermediate. In preclinical studies, Cefolesis had better MIC50s than Ceftazidime against Streptococcus pneurnoniae or Staphflococcus aureus (methicillin-sensitive MSSA or resistant MRSA) and showed significant antibacterial activity against Citrobacter and Enterobacter. Cefolesis is well tolerated in clinical studies, being eliminated mainly via glomerular filtration in humans.

VerwendenCefoselis sulfate belongs to the fourth generation of ultra-broad-spectrum cephalosporins, exhibiting potent antibacterial activity against Gram-positive bacteria including staphylococci, pneumococci, and streptococci, as well as Gram-negative bacteria such as Pseudomonas, Escherichia coli, Klebsiella pneumoniae, Enterobacter species, and Serratia marcescens. It is primarily indicated for infections caused by susceptible bacteria, including respiratory tract infections, urinary tract infections, biliary tract infections, and intra-abdominal infections.Cefoselis sulfate exhibits high sensitivity against Streptococcus pneumoniae, group ABC streptococci, methicillin-susceptible Staphylococcus aureus, and non-enzyme-producing staphylococci. Its antimicrobial activity surpasses that of cefotiam, cefoperazone, cefotaxime, and ceftriaxone. It exhibits potent antibacterial activity against Streptococcus pyogenes, Streptococcus viridans, and Streptococcus bovis, with an MIC90 of 0.06 mg/L. It demonstrates good antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA), with an MIC90 of 16 mg/L, exhibiting superior activity to most cephalosporin antibiotics.